Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Dimitra Bourboulia Clear advanced filters

  • Molecular chaperones establish essential protein-protein interaction networks. Modified versions of these assemblies are generally enriched in certain maladies. A study published in Nature Communications used epichaperomics to identify unique changes occurring in chaperone-formed protein networks during mitosis in cancer cells.

    • Mark R. Woodford
    • Dimitra Bourboulia
    • Mehdi Mollapour
    Comments & OpinionOpen Access
    Nature Communications
    Volume: 14, P: 1-3

  • Heritz et al. use an orthogonal approach to identify a selective inhibitor for HIF2α that disrupts its interaction with the molecular chaperone Hsp70. This inhibitor utilizes an alternative mechanism of action to previous HIF2α antagonists, providing a promising approach in addressing kidney cancer drug resistance.

    • Jennifer A. Heritz
    • Sarah J. Backe
    • Gennady Bratslavsky
    ResearchOpen Access
    Communications Medicine
    Volume: 6, P: 1-13

  • Hsp90 is required for the folding, stability and activity of several drivers of oncogenesis. Here the authors show that Folliculin-interacting proteins (FNIP) 1 and 2, whose expression correlates with the cellular response to Hsp90 inhibitors, are co-chaperones of Hsp90 that function by inhibiting its ATPase activity.

    • Mark R. Woodford
    • Diana M. Dunn
    • Mehdi Mollapour
    ResearchOpen Access
    Nature Communications
    Volume: 7, P: 1-15

  • Several therapeutic options for the treatment of renal cell carcinoma (RCC) are available, but challenges in the field such as drug resistance still exist. In this Perspective, Sager et. al discuss the role and the inhibition of the cyclin-dependent kinases CDK4 and CDK6 in RCC. The role of CDK4/6 at the interface between metabolic signalling pathways and cell cycle, the wide use of CDK4/6 inhibitors in cancer treatment, and promising preclinical studies testing these drugs in RCC support further investigation of CDK4/6 targeting in RCC.

    • Rebecca A. Sager
    • Sarah J. Backe
    • Mehdi Mollapour
    Reviews
    Nature Reviews Urology
    Volume: 19, P: 305-320